DPP4 Inhibition, NPY$_{1-36}$, PYY$_{1-36}$, SDF-1α and a Hypertensive Genetic Background
Conspire to Augment Cell Proliferation and Collagen Production: Effects That Are
Abolished by Low Concentrations of 2-Methoxyestradiol

Edwin K. Jackson, Delbert G. Gillespie and Stevan P. Tofovic

Department of Pharmacology and Chemical Biology
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15219
RUNNING TITLE PAGE

Running Title: Combinatorial Effects of DPP4 Substrates

Address for Correspondence:

Dr. Edwin K. Jackson
Department of Pharmacology and Chemical Biology
100 Technology Drive, Room 514
University of Pittsburgh School of Medicine
Pittsburgh, PA 15219
tel: 412-648-1505
Fax: 412-624-7050
E-mail: edj@pitt.edu

Number of Text Pages: 45
Number of Tables: Main Text, 0; Online Data Supplement, 7
Number of Figures: 10
Number of References: 87
Number of Words in the Abstract: 250
Number of Words in Introduction: 797
Number of Words in Discussion: 2268

List of Abbreviations: analysis of variance (ANOVA); cardiac fibroblasts (CFs); dipeptidyl peptidase 4 (DPP4); dipeptidyl peptidase 4 inhibitors (DPP4Is); 2-hydroxyestradiol (2HE); glomerular mesangial glomerular cells (GMCs); 2-methoxyestradiol (2ME); neuropeptide Y1-36 (NPY1-36); neuropeptide Y3-36 (NPY3-36); peptide YY1-36 (PYY1-36); peptide YY3-36 (PYY3-36); preglomerular vascular smooth muscle cells (PGVSMCs); platelet derived growth factor–BB (PDGF-BB); spontaneously hypertensive rats (SHR); stromal cell-derived factor 1α (SDF-1α); Wistar-Kyoto rats (WKY); Y1 receptors (Y1Rs); rough endoplasmic reticulum (RVR).

Recommended Section Assignment: Cardiovascular
ABSTRACT

By reducing their metabolism, dipeptidyl peptidase 4 inhibition (DPP4I) enhances the effects of numerous peptides including neuropeptide Y₁₋₃₆ (NPY₁₋₃₆), peptide YY₁₋₃₆ (PYY₁₋₃₆) and SDF-1α. Studies show that separately NPY₁₋₃₆, PYY₁₋₃₆ and SDF-1α stimulate proliferation of, and collagen production by, cardiac fibroblasts (CFs), preglomerular vascular smooth muscle cells (PGVSMCs) and glomerular mesangial glomerular cells (GMCs), particularly in cells isolated from genetically-hypertensive rats. Whether certain combinations of these factors, in the absence or presence of DPP4I, are more pro-fibrotic than others is unknown. Here we contrasted 24 different combinations of conditions [DPP4I, hypertensive genotype and physiological levels (3 nmol/L) of NPY₁₋₃₆, PYY₁₋₃₆ or SDF-1α] on proliferation of, and [³H]-proline incorporation by, CFs, PGVSMCs and GMCs. In all three cell types, the various treatment conditions differentially increased proliferation and [³H]-proline incorporation, with a hypertensive genotype+DPP4I+NPY₁₋₃₆+SDF-1α being the most efficacious combination. Although the effects of this 4-way combination were similar in male versus female CFs, physiological (1 nmol/L) concentrations of 2-methoxyestradiol (2ME; non-estrogenic metabolite of 17β-estradiol), abolished the effects of this combination in both male and female CFs. In conclusion, this study demonstrates that CFs, PGVSMCs and GMCs are differentially activated by various combinations of NPY₁₋₃₆, PYY₁₋₃₆, SDF-1α, a hypertensive genetic background and DPP4I. We hypothesize that as these pro-growth conditions accumulate, a tipping point would be reached that manifests in the long term as organ fibrosis and that 2ME would obviate any pro-fibrotic effects of DPP4I, even under the most pro-fibrotic conditions (i.e, hypertensive genotype with high NPY₁₋₃₆+SDF-1α levels and low 2ME levels).
SIGNIFICANCE STATEMENT

This work elucidates combinations of factors that could contribute to long-term pro-fibrotic effects of dipeptidyl peptidase 4 inhibitors and suggests a novel drug combination that could prevent any potential pro-fibrotic effects of DPP4 inhibitors while augmenting the protective effects of this class of antidiabetic agents.
INTRODUCTION

The pharmacology of dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4Is), a class of antidiabetic drugs, is complex. Although inhibition of DPP4 increases incretin levels and thereby augments insulin release (McIntosh et al., 2005), DPP4Is also elevate concentrations of other biologically-active DPP4 substrates (Mentlein, 1999; Gorrell, 2005; Mulvihill and Drucker, 2014); and this likely contributes to the net effects of DPP4Is. For example, neuropeptide Y_{1-36} (NPY_{1-36}) and peptide YY_{1-36} (PYY_{1-36}), which are potent endogenous agonists of Gi-coupled Y_{1} receptors (Y_{1}Rs) (Michel et al., 1998; Berglund et al., 2003), are metabolized by DPP4 to neuropeptide Y_{3-36} (NPY_{3-36}) and peptide YY_{3-36} (PYY_{3-36}), respectively (Mentlein, 1999; McIntosh et al., 2005). Because PYY_{1-36} and NPY_{1-36} are potent Y_{1}R agonists whereas PYY_{3-36} and NPY_{3-36} are inactive at Y_{1}Rs (Michel et al., 1998; Berglund et al., 2003), DPP4Is increase Y_{1}R activation by impairing the metabolism of NPY_{1-36} and PYY_{1-36}. In support of this concept, recent studies by Wilson and coworkers show that DPP4 inhibition increases plasma NPY_{1-36} yet decreases plasma NPY_{3-36} or PYY_{3-36} in hypertensive patients with type 2 diabetes (Wilson et al., 2019). Thus DPP4Is may modify the biological effects of endogenous NPY_{1-36} and PYY_{1-36}. Indeed, our recent results show that via Y_{1}Rs NPY_{1-36} and PYY_{1-36}, but not NPY_{3-36} or PYY_{3-36}, stimulate proliferation of, and collagen production by, cardiac fibroblasts (CFs), preglomerular vascular smooth muscle cells (PGVSMCs) and glomerular mesangial cells (GMCs) (Jackson et al., 2012; Zhu et al., 2015b); and these effects of NPY_{1-36} and PYY_{1-36} are enhanced by DPP4 inhibition (Jackson et al., 2012; Zhu et al., 2015b).

The chemokine SDF-1α is another important DPP4 substrate. SDF-1α, a 68 amino acid polypeptide, is a potent CXCR4-receptor agonist, which like Y_{1}Rs are Gi-coupled (Busillo and Benovic, 2007). However, DPP4 cleaves 2 amino acids from the N-terminus of SDF-1α, and this truncated form of SDF-1α is inactive at CXCR4 receptors (Wang et al., 2014). Our most recent results show that SDF-1α, via CXCR4 receptors, induces proliferation of, and collagen production by, CFs, PGVSMCs and GMCs; and these effects are also enhanced by DPP4
inhibition (Jackson et al., 2017). Importantly, DPP4 inhibition increases SDF-1α levels in patients with type 2 diabetes (Fadini et al., 2010).

Pro-growth and pro-fibrotic effects of NPY1-36, PYY1-36 and SDF-1α on CFs, PGVSMCs and GMCs depend in part on the blood pressure of the animals from which cells were obtained. For example, our previous results demonstrate that CFs, PGVSMCs and GMCs harvested from spontaneously hypertensive rats (SHR) are more responsive to the pro-growth/pro-fibrotic actions of NPY1-36, PYY1-36 and SDF-1α than are cells obtained from normotensive Wistar-Kyoto rats (WKY) (Jackson et al., 2012; Cheng et al., 2013; Zhu et al., 2015b; Jackson et al., 2017).

Because overactive CFs can contribute to cardiac fibrosis leading to heart failure (Brown et al., 2005) and proliferation of, and collagen production by, PGVSMCs and GMCs can lead to renovascular hypertrophy, glomerulosclerosis, renal fibrosis and renal failure (Dubey et al., 1997), the effects of DPP4Is on growth responses to DPP4 peptide substrates must be thoroughly evaluated. An unanswered question is: How important are the combinatorial effects of NPY1-36, PYY1-36, SDF-1α, DPP4 inhibition and genetic hypertension as stimulators of proliferation of, and collagen production by, CFs, PGVSMCs and GMCs? This is a key question since in patients with cardiovascular diseases some will have hypertension with co-elevation of NPY1-36, PYY1-36, and SDF-1α. For example, in heart patients SDF-1α levels are increased and are associated with heart failure, cardiac fibrosis and all-cause mortality (Chu et al., 2010; Subramanian et al., 2014; Zuern et al., 2015). Simultaneously, the release of NPY1-36 from sympathetic nerves is augmented in heart failure (Hulting et al., 1990; Kaye et al., 1994). Also PYY1-36 levels are elevated in advanced heart failure (Gouya et al., 2014). Indeed, Packer has proposed that DPP4Is cause heart failure by increasing levels of both NPY1-36 and SDF-1α, thus promoting central and peripheral sympathetic activation (Packer, 2018).

Together, the aforementioned findings suggest that combinatorial effects of small increases of NPY1-36, PYY1-36 and SDF-1α may have large effects on CFs, PGVSMCs and GMCs that are further amplified by DPP4Is and hypertension. To test this concept, here we
examined 24 different combinations of genotype, peptide treatments and DPP4 inhibition on the activation of CFs, PGVSMCs and GMCs. Our results confirm that the effects of NPY$_{1-36}$, PYY$_{1-36}$, SDF-1α and DPP4 inhibition are context dependent due to combinatorial effects of these agents with genetic hypertension. Moreover, our studies show that a low, physiological concentration of 2-methoxyestradiol (2ME), an antidiabetic and cardiorenal-protective metabolite of 17β-estradiol, abrogates the pro-growth/pro-fibrotic of the most efficacious combination of factors (i.e., DPP4 inhibition + genetic hypertension + NPY$_{1-36}$ + SDF-1α). We hypothesize that these findings may help identify patients at greatest risk of adverse long-term consequences of DPP4Is and suggest that co-administration of 2ME might improve upon the beneficial effects of DPP4Is.
MATERIALS and METHODS

Materials. Chemicals were from the following sources: SDF-1α (ProSpec: Rehovot, Israel); sitagliptin (Merck: Whitehouse Station, NJ); platelet derived growth factor–BB (PDGF-BB), NPY1-36 and PYY1-36 (Sigma-Aldrich: St. Louis, MO); 2-methoxyestradiol (Steraloids: Newport, RI).

Animals. Male and female SHR and WKY rats (approximately 12 weeks of age) were obtained from Charles River Laboratories (Wilmington, MA). The University of Pittsburgh Institutional Animal Care and Use Committee approved all procedures. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (8th edition, 2011). Our rationale for employing SHR cells is three-fold. First, our previous studies show that the pro-growth and pro-fibrotic effects of NPY1-36, PYY1-36 and SDF-1α on CFs, PGVSMCs and GMCs are greater in cells harvested from SHR (Jackson et al., 2012; Cheng et al., 2013; Zhu et al., 2015b; Jackson et al., 2017). Second, we have previously published that both WKY and SHR CFs, PGVSMCs and GMCs express both DPP4 protein and DPP4 activity and that there is no difference between WKY and SHR cells in this regard. (Jackson et al., 2012) (Zhu et al., 2015b). Third, SHR express pathophysiological mechanisms and pharmacological responses similar to type 2 diabetic, hypertensive patients. For example, like type 2 diabetic patients, SHR have insulin resistance (Umeda et al., 2003) and increased oxidative stress (Chen et al., 2019); and like diabetic patients, SHR are highly responsive to angiotensin converting enzyme inhibitors (Kost et al., 1995).

Cell Cultures. CFs, GMCs and PGVSMCs were isolated from SHR and WKY and characterized as previously described in detail by us (Inoue et al., 1998; Zhu et al., 2015b; Zhu and Jackson, 2017).

Assessment of Cell Proliferation. Each well of a 12-well plate was seeded with 5,000 cells. Cells were maintained in phenol red-free DMEM/F12 containing 10% steroid-free fetal
bovine serum under standard tissue culture conditions. Three days later when cells were approximately 60 to 70% confluent, cells were growth-arrested for 2 days in DMEM/F12 containing 0.4% bovine serum albumin. Next, cells were placed in DMEM/F12 containing a low concentration (25 ng/mL) of PDGF-BB and then treated every day for 4 days with various treatments. Cells were then harvested and cell number quantified, in a blinded fashion, using a Nexcelom Cellometer Auto T4 cell counter (Nexcelom Bioscience: Lawrence, MA).

**Assessment of \[^3\text{H}\]-Proline Incorporation.** Cells were prepared as described above with the exception that cells were allowed to achieve a confluent monolayer (usually 5 to 6 days after seeding). Then cells were made quiescent in DMEM supplemented with 0.4% bovine serum albumin. To initiate proline incorporation, growth-arrested cells were placed in DMEM with added PDGF-BB (25 ng/ml) and \[^3\text{H}\]-L-proline (2 µCi/mL) and containing various treatments. After 36 hours, experiments were terminated by washing cells twice with phosphate-buffered saline (PBS) and twice with ice-cold trichloroacetic acid (10%). The precipitate was solubilized in 0.5 ml of 0.3 N NaOH and 0.1% SDS and radioactivity determined, in a blinded fashion, in the precipitate using a liquid scintillation counter.

**Assessment of Release of Collagen I Into the Extracellular Compartment.** Each well of a 6-well plate was seeded with 50,000 cells. Cells were maintained in phenol red-free DMEM/F12 containing 10% steroid-free fetal bovine serum under standard tissue culture conditions. Three days later when cells were approximately 60% confluent, cells were growth-arrested for 2 days in DMEM/F12 containing 0.4% bovine serum albumin. Next, cells were placed in DMEM/F12 containing a low concentration (25 ng/mL) of PDGF-BB and then treated every day for 3 days with treatments. The conditioned medium was collected at 24, 48 and 72 hours, combined and assayed for collagen I. After 72 hours of treatment, cells were collected and pelleted by centrifugation and the supernatant was removed. Cells were then washed 3 times with PBS, and then resuspended in PBS. Next, cells were lysed by ultrasonication 4 times, centrifuged at 1500×g for 10 minutes at 2-8°C to remove cellular debris, and the
supernatant was assayed for collagen I. Collagen I in both the conditioned medium and cell lysate was measured using the LSBio (Seattle, WA) Rat Collagen I ELISA Kit (catalog number, LS-F37378). Since membrane-delimited collagen I (i.e., collagen I within endoplasmic reticulum, Golgi apparatus and secretory vesicles) would not be available for binding to capture and detection antibodies, the analysis of collagen I in cell lysate provides information related to predominantly cytosolic collagen I.

**Protocol 1: Experimental Design and Statistics.** To clarify the “biological replicate,” our protocol design is illustrated in Figure 1. The protocol entailed 12 batches of CFs, with each batch derived from a separate male rat (i.e., a total of 12 rats; 6 WKY and 6 SHR). In the case of GMCs or PGVSMCs, the protocol again entailed 12 distinct batches of cells; however, because sufficient numbers of GMCs and PGVSMCs cannot be obtained from 1 rat, each batch of cells was derived from a separate set of 3 male rats [i.e., a total of 12 sets of 3 rats; 6 sets of 3 WKY and 6 sets of 3 SHR]. Thus a single biological replicate was a unique rat or a unique set of 3 rats. Cells from each WKY biological replicate were seeded on a 12-well plate, and cells from each SHR biological replicate were seeded on another identical 12-well plate. There were 12 different treatments for each plate (i.e., for each plate, each well of cells received 1 of 12 treatments). All plates received the same 12 treatments. Next, the plate of WKY cells and a plate of SHR cells were placed side-by-side in a cell incubator. After the indicated incubation time, either cell proliferation or [³H]-proline synthesis was measured (different set of cultures were required for the two outcome measures). We considered this one experiment. Next, the entire procedure was repeated 5 times on different occasions (i.e., sample size was n=6 for WKY cells and n=6 for SHR cells). Results were analysed by a nested 3-factor analysis of variance (ANOVA) in which one factor was genotype (fixed factor; levels were WKY or SHR ), a second factor was plate number (nested under genotype) and the third factor was treatment [fixed factor; 12 treatment levels which were various peptide treatments (vehicle, NPY₁-36, PYY₁-36, SDF-1α, NPY₁-36+SDF-1α, PYY₁-36+SDF-1α) with or without the DPP4 inhibitor sitagliptin.
Post-hoc tests were conducted using the Bonferroni method to control for multiple comparisons. We used a sitagliptin concentration of 1 μmol/L because we have previously shown that this concentration inhibits the metabolism of PYY\textsubscript{1-36} to PYY\textsubscript{3-36} in PGVSMCs and GMCs (Jackson et al., 2012). We used concentrations of NPY\textsubscript{1-36}, PYY\textsubscript{1-36} and SDF-1α of 3 nmol/L because with all 3 peptides, this concentration provides a low (just above threshold) stimulation of cell growth in WKY cells (Zhu et al., 2015b; Jackson et al., 2017). Also the concentration of 3 nmol/L approximates achievable in vivo tissue levels of NPY\textsubscript{1-36}, PYY\textsubscript{1-36} and SDF-1α (Schmidt et al., 2005; Kuncova et al., 2011; Roux et al., 2012).

**Protocol 2: Experimental Design and Statistics.** Figure 2 illustrates the design of Protocol 2. CFs from a specific male or female SHR (referred to as “male CFs” or “female CFs”, respectively) were seeded on a separate 12-well plate, and 9 wells received 1 of 9 treatments [vehicle, NPY\textsubscript{1-36}, SDF-1α, NPY\textsubscript{1-36}+SDF-1α, sitagliptin, sitagliptin+NPY\textsubscript{1-36}, sitagliptin+SDF-1α, sitagliptin+NPY\textsubscript{1-36}+SDF-1α, 2ME+sitagliptin+NPY\textsubscript{1-36}+SDF-1α], and the 2 plates was placed together in a cell incubator. All plates received the same 9 treatments. The concentrations of peptides and sitagliptin were the same as in Protocol 1. The concentration of 2ME (1 nmol/L) was selected based on the physiological levels of this 17β-estradiol metabolite (Zacharia et al., 2003; Barchiesi et al., 2006). After the indicated incubation time, cell proliferation was measured. We considered this one experiment. Next, the entire procedure was repeated 4 times on different occasions (i.e., sample size was n=5 for male CFs and n=5 for female CFs). The effects of treatments in male and female CFs were analysed separately by 3-factor ANOVA in which one factor was plate number (random factor), a second factor was peptide treatment (fixed factor; levels were vehicle, NPY\textsubscript{1-36}, SDF-1α, NPY\textsubscript{1-36}+SDF-1α) and the third factor was sitagliptin treatment (fixed factor; without and with sitagliptin). The effects of 2ME on responses to sitagliptin+NPY\textsubscript{1-36}+SDF-1α were analyzed by a 2-factor ANOVA in which one factor was plate number (random factor) and the second factor was treatment group (vehicle,
sitagliptin+NPY_{1-36}+SDF-1\alpha, 2ME+sitagliptin+NPY_{1-36}+SDF-1\alpha). Post-hoc tests were conducted using the Bonferroni method to control for multiple comparisons.

**Protocol 3: Experimental Design and Statistics.** Protocol 3 was conducted in CFs obtained from 5 male SHR. Two matching 6-well plates of CFs were prepared from each SHR. One plate was treated with sitagliptin (1 \mu mol/L) plus DPP4 substrates (NPY_{1-36} and SDF-1\alpha; 3 nmol/L each) and the other was treated with vehicle plus DPP4 substrates (control). For each group the outcome assessment was intracellular (cytosolic) and extracellular (medium) collagen I levels, and the ratio of extracellular to intracellular collagen I. These values were obtained for each paired set of SHR CFs by averaging the results for the replicates on each plate. The results were statistically analysed using a paired t-tailed Student’s t-test (n=5) since control and sitagliptin-treated cells were from the same biological replicate (i.e., same SHR).
RESULTS

Proliferation Studies in CFs. Figure 3 provides a summary of the effects of the 24 different treatments on proliferation of CFs. To facilitate visualization of the relative effects of the treatments on CF proliferation, the treatments are listed in order on the horizontal axis from least active (far left) to most active (far right). Statistical analysis by ANOVA revealed an overall effect of cell genotype (P<0.0001) and treatments (P<0.0001) on CF proliferation. Moreover there was a significant genotype x treatment interaction (P<0.0001). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 2 (which lists the results of all possible comparisons, while Supplemental Table 1 lists the group assignment numbers for Supplemental Table 2). Bonferroni tests showed that proliferation was significantly greater in WKY CFs treated with sitagliptin+NPY_{1-36}+SDF-1α compared with all other WKY CF groups and showed that compared with all of the other 23 groups, the most proliferative combination was SHR CFs treated with sitagliptin+NPY_{1-36}+SDF-1α. This analysis also demonstrated significantly increased proliferation in the order: WKY < SHR < SHR+NPY_{1-36} < SHR+NPY_{1-36}+SDF-1α < sitagliptin+SHR+NPY_{1-36}+SDF-1α; and WKY < SHR < SHR+PYY_{1-36} < SHR+PYY_{1-36}+SDF-1α < sitagliptin+SHR+PYY_{1-36}+SDF-1α.

[^H]-Proline Incorporation Studies in CFs. To assess the effects of the 24 different treatments on total collagen production, we measured the effects of treatments on [^H]-proline incorporation in CFs that were both confluent and quiescent as previously described (Barchiesi et al., 2002; Dubey et al., 2003a; Dubey et al., 2010; Zhu et al., 2015b; Jackson et al., 2017). Since proline is abundant (enriched) in all isoforms of collagen, this approach permits an assessment of total collagen production. Also, by conducting these experiments in confluent/quiescent cells, incorporation of [^H]-proline in non-collagen proteins could be minimized and increases in [^H]-proline incorporation could be assessed at a constant cell number.
Figure 4 summarizes the relative effects of the 24 different treatment conditions on [³H]-proline incorporation by CFs. As with Figure 3, the results are organized in Figure 4 (as well as in Figures 5-8) in order of treatment efficacy starting from the least active (left) to the most active (right) treatments on the horizontal axis. As with CF proliferation, statistical analysis by ANOVA showed that genotype (P<0.0001) and treatments (P<0.0001) significantly increased [³H]-proline incorporation by CFs and that there was a significant interaction between genotype and treatments (P=0.0010). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 3. Bonferroni tests showed that [³H]-proline incorporation was significantly greater in WKY CFs treated with sitagliptin+NPY₁₋₃₆+SDF-1α compared with all other WKY CF groups and showed that compared with all of the other 23 groups, [³H]-proline incorporation was greatest in SHR CFs treated with sitagliptin+NPY₁₋₃₆+SDF-1α. This analysis also demonstrated significantly increased [³H]-proline incorporation in the order: WKY < SHR < SHR+NPY₁₋₃₆ < SHR+NPY₁₋₃₆+SDF-1α < sitagliptin+SHR+NPY₁₋₃₆+SDF-1α; and WKY < SHR < SHR+PYY₁₋₃₆ < SHR+PYY₁₋₃₆+SDF-1α = sitagliptin+SHR+PYY₁₋₃₆+SDF-1α.

Proliferation Studies in PGVSMCs. Figure 5 provides a summary of the effects of the 24 different treatments on proliferation of PGVSMCs. Statistical analysis by ANOVA revealed an overall effect of cell genotype (P=0.0001) and treatments (P<0.0001) on PGVSMC proliferation. Moreover there was a significant genotype x treatment interaction (P<0.0001). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 4. Bonferroni tests showed that proliferation was significantly greater in WKY PGVSMCs treated with sitagliptin+NPY₁₋₃₆+SDF-1α compared with all other WKY PGVSMC groups and showed that compared with all of the other 23 groups, the most proliferative combination was SHR PGVSMCs treated with sitagliptin+NPY₁₋₃₆+SDF-1α. This analysis also demonstrated significantly increased proliferation in the order: WKY = SHR < SHR+NPY₁₋₃₆ < SHR+NPY₁₋₃₆+SDF-1α.
\[36+SDF-1\alpha < \text{sitagliptin+SHR+NPY}_{1-36}+SDF-1\alpha; \text{ and WKY} = \text{SHR} < \text{SHR+PYY}_{1-36} < \text{SHR+PYY}_{1-36}+SDF-1\alpha < \text{sitagliptin+SHR+NPY}_{1-36}+SDF-1\alpha.\]

[\[^{3}H\]-Proline Incorporation Studies in PGVSMCs. Figure 6 summarizes the relative effects of the 24 different treatment conditions on \[^{3}H\]-proline incorporation by PGVSMCs. ANOVA showed that genotype (\(P<0.0001\)) and treatments (\(P<0.0001\)) significantly increased \[^{3}H\]-proline incorporation by PGVSMCs and that there was a significant interaction between genotype and treatments (\(P=0.0011\)). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 5. Bonferroni tests showed that \[^{3}H\]-proline incorporation was significantly greater in WKY PGVSMCs treated with sitagliptin+NPY\(_{1-36}\)+SDF-1\alpha compared with all other WKY PGVSMC groups and showed that compared with all of the other 23 groups, \[^{3}H\]-proline incorporation was greatest in SHR PGVSMCs treated with sitagliptin+NPY\(_{1-36}\)+SDF-1\alpha. This analysis also demonstrated significantly increased \[^{3}H\]-proline incorporation in the order: WKY < SHR < SHR+NPY\(_{1-36}\) < SHR+NPY\(_{1-36}\)+SDF-1\alpha < sitagliptin+SHR+NPY\(_{1-36}\)+SDF-1\alpha; and WKY < SHR < SHR+PYY\(_{1-36}\) < SHR+PYY\(_{1-36}\)+SDF-1\alpha = sitagliptin+SHR+PYY\(_{1-36}\)+SDF-1\alpha.

Proliferation Studies in GMCs. Statistical analysis by ANOVA (Figure 7) showed that genotype (\(P<0.0001\)) and treatments (\(P<0.0001\)) significantly increased proliferation of GMCs and that there was a significant interaction between genotype and treatments (\(P<0.0001\)). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 6. Bonferroni tests showed that proliferation was significantly greater in WKY GMCs treated with sitagliptin+NPY\(_{1-36}\)+SDF-1\alpha compared with all other WKY GMC groups and showed that compared with all of the other 23 groups, proliferation was greatest in SHR GMCs treated with sitagliptin+NPY\(_{1-36}\)+SDF-1\alpha. This analysis also demonstrated significantly increased proliferation in the order: WKY < SHR < SHR+NPY\(_{1-36}\) < SHR+NPY\(_{1-36}\)+SDF-1\alpha < sitagliptin+SHR+NPY\(_{1-36}\)+SDF-1\alpha; and WKY < SHR < SHR+PYY\(_{1-36}\) < SHR+PYY\(_{1-36}\)+SDF-1\alpha < sitagliptin+SHR+PYY\(_{1-36}\)+SDF-1\alpha.
[³H]-Proline Incorporation Studies in GMCs. Figure 8 summarizes the relative effects of the 24 different treatment conditions on [³H]-proline incorporation by GMCs. ANOVA showed that treatments (P<0.0001) significantly increased [³H]-proline incorporation by GMCs and that there was a significant interaction between genotype and treatments (P=0.0006). Bonferroni tests were conducted to compare all possible pairs and the results are shown in Supplemental Table 7. Bonferroni tests showed that [³H]-proline incorporation was significantly greater in WKY GMCs and SHR GMCs treated with sitagliptin+NPY₁-36+SDF-1α compared with all other GMC groups except each other and the SHR+NPY₁-36+SDF-1α group.

Proliferation Studies in Female versus Male CFs. In general, the results described above indicate that NPY₁-36 and SDF-1α separately stimulate cell proliferation and [³H]-proline incorporation, and that the two combined are more efficacious than each separately. Our results also indicate that inhibiting DPP4 with sitagliptin further augments the effects of NPY₁-36 plus SDF-1α, as does a hypertensive genetic background.

Another important biological variable is sex. To explore whether NPY₁-36 and SDF-1α stimulate proliferation in female cells, we examined the effects of these two peptides alone and in combination in female CFs. In these studies we used SHR CFs since CFs with a hypertensive genetic background respond more robustly than cells from normotensive animals. We conducted these experiments in both the absence and presence of sitagliptin to determine whether in female cells the effects of these peptide treatments are augmented by inhibition of DPP4. For comparison, we included a new group of male CFs in the same experimental series with the female CFs.

Figure 9 summarizes the effects of NPY₁-36 alone, SDF-1α alone and NPY₁-36+SDF-1α in female SHR CFs without (panel A) and with (panel B) sitagliptin. Panels C and D show comparable data for male SHR CFs. Importantly, in female SHR CFs analysis by ANOVA revealed a significant effect of the peptide treatments (P<0.0001) and sitagliptin (P<0.0001) on CF proliferation and demonstrated a significant interaction between peptide treatments and
sitagliptin \((P=0.0026)\). Also the combination of NPY\(_{1-36}\)+SDF-1α was more effective with regard to stimulating proliferation compared to each of the peptides per se. Overall, the effects of NPY\(_{1-36}\), SDF-1α and NPY\(_{1-36}\)+SDF-1α in the absence and presence of sitagliptin were similar in female and male CFs.

This experiment with female and male CFs confirms that the combination of DPP4 inhibition, NPY\(_{1-36}\) and SDF-1α is a powerful stimulus of SHR CF proliferation and that sex chromosomes per se do not affect the pro-proliferative effects of this combination. However, these experiments were performed in the absence of female hormones. Our previous studies show that 17β-estradiol is a potent inhibitor of cell proliferation (CFs, GMCs and vascular smooth muscle cells) induced by fetal bovine serum and that this effect of 17β-estradiol is mediated entirely by the conversion of 17β-estradiol to 2-methoxyestradiol (2ME) (Dubey et al., 1998; Dubey et al., 2000; Dubey et al., 2001; Xiao et al., 2001; Zacharia et al., 2001; Barchiesi et al., 2002; Zacharia et al., 2002; Dubey et al., 2003a; Dubey et al., 2003b; Zacharia et al., 2003; Dubey et al., 2004; Barchiesi et al., 2006; Dubey et al., 2007; Dubey and Jackson, 2009; Barchiesi et al., 2010; Rigassi et al., 2015), a major metabolite of 17β-estradiol. Whether physiological concentrations of 2ME abrogate the combined effects of DPP4 inhibition, NPY\(_{1-36}\) and SDF-1α is an open question. To address this question, we compared the effects of vehicle-treated (control) SHR CFs versus SHR CFs treated with sitagliptin+NPY\(_{1-36}\)+SDF-1α versus SHR CFs treated with 2ME+sitagliptin+NPY\(_{1-36}\)+SDF-1α. As shown in Figure 10, 1 nmol/L of 2ME completely prevented the pro-proliferative effects of sitagliptin+NPY\(_{1-36}\)+SDF-1α in both male and female SHR CFs.

**Assessment of Release of Collagen I into the Extracellular Compartment by Sitagliptin.** Following synthesis at and simultaneous transport into the rough endoplasmic reticulum (RER), collagens are processed in the Golgi apparatus and compartmentalized into secretory granules that under exocytosis, which results in the release of collagens into the extracellular compartment (Rodriguez-Feo et al., 2005). Because \(^{3}H\)-proline is incorporated
into collagens at the RER, [³H]-proline incorporation permits assessment of total collagen production, regardless of collagen isoform or location within the membrane-delimited secretory pathway. However, [³H]-proline can be incorporated into non-collagen proteins. Although removal of non-collagen proteins from collagen proteins can be accomplished using a multi-step procedure (Peterkofsky and Diegelmann, 1971; Peterkofsky, 1972), this method relies upon pan-antibodies and requires a large number of sample manipulations. These drawbacks decrease sensitivity and increase variability. An alternative method, and the one employed here, is to measure [³H]-proline incorporation in confluent/quiescent cells to minimize [³H]-proline incorporation into non-collagen proteins. However, confluent/quiescent cells produce less collagen (Peterkofsky, 1972) and secrete only approximately 5% of synthesized collagen (Peterkofsky, 1972). Consequently, assessment of secreted collagen using [³H]-proline incorporation in confluent/quiescent cells is problematic. Here we applied an alternative method using a sandwich ELISA assay to measure specifically the effects of sitagliptin on secreted collagen I. Collagen I was specifically targeted since this collagen isoform is one of the most abundantly expressed in cardiac fibroblasts (Namba et al., 1997). In these experiments, collagen I was measured in both cell lysates (which measures free collagen within the cell that is not membrane delimited, and therefore can bind to the capture and detection antibodies) and conditioned medium (which measures collagen secreted into the extracellular compartment). The ratio of extracellular to intracellular collagen I was calculated as an index of secretion efficiency. Shown in Figure 11, in cells treated with DPP4 substrates, sitagliptin significantly decreased intracellular (cytosolic) collagen I (panel A; $P=0.0034$), increased extracellular collagen I (panel B; $P=0.0130$) and increased the ratio of extracellular to intracellular collagen (panel C; $P=0.0058$).
DISCUSSION

The pharmacological effects of DPP4Is are context dependent (Jackson, 2017). For example, whether DPP4Is increase, decrease or have no effect on blood pressure in rats is strain dependent (Jackson et al., 2015). Similarly, in metabolic-syndrome patients, DPP4Is can induce antihypertensive or pro-hypertensive effects depending on the degree of ACE inhibition (Marney et al., 2010). Our working hypothesis is that the context-dependent effects of DPP4Is are due to the fact that DPP4 metabolizes many biologically-active peptides (Mentlein, 1999; Gorrell, 2005; Klemann et al., 2016). Consequently, the overall effects of DPP4Is depends on the complex milieu of DPP4 substrates. Indeed, studies in humans indicate that DPP4Is can alter the physiological responses to several DPP4 substrates including substance P (Devin et al., 2014), growth hormone-releasing hormone (Wilson et al., 2018) and NPY1-36 (Hubers et al., 2018).

Our lab has been investigating whether DPP4 substrates can influence the proliferation of, and collagen production by, CFs, PGVSMCs and GMCs. This work revealed that DPP4 inhibition enhances the pro-growth effects of NPY1-36 and PYY1-36 (mediated via Y1 receptors) (Jackson et al., 2012; Zhu et al., 2015b), as well as the pro-growth effects of SDF-1α (mediated by CXCR4 receptors) (Jackson et al., 2017). In these studies, our focus was on the proliferation of, and collagen production by, CFs, PGVSMCs and GMCs because such responses by these cell types can lead to cardiac and renal fibrosis and dysfunction. The clinical relevance of our findings is underscored by the facts that several randomized clinical trials, observational studies and FDA evaluation support the conclusion that DPP4Is increase the risk of heart failure (Packer, 2018).

Our previous results with NPY1-36, PYY1-36 and SDF-1α suggest that the effects of DPP4 inhibitors on cellular activity of CFs, PGVSMCs and GMCs may depend on the combination of effects of multiple stimuli including combinations of peptides and genetic background. Thus, the explicit goal of the present study was to evaluate this hypothesis by conducting a careful head-
to-head comparison of cell proliferation and collagen production in CFs, PGVSMCs and GMCs under highly controlled conditions in which cells were exposed to combinations of treatment conditions.

Important aspects of our experimental design were: 1) the selection of concentrations of NPY<sub>1-36</sub>, PYY<sub>1-36</sub> and SDF-1α; 2) the utilization of cells from both genetically normotensive and hypertensive animals; 3) the rigorous adherence to appropriate biological replicates; and 4) the assessment of both total cellular collagen in non-proliferating cells, as well as secreted collagen I in proliferating (active) cells. The concept we addressed was that even with very low concentrations of DPP4 substrates, under the appropriate combinatorial conditions (including genetic hypertension) cellular activity can be markedly influenced by DPP4Is. This, we felt, would model the in vivo condition in which several factors combined can have biologically, and possible clinically, meaningful effects which are much larger than the effects of any one given factor. Here we chose 3 nmol/L because with all 3 peptides, this concentration provides a threshold stimulation of cell growth in WKY cells (Zhu et al., 2015b; Jackson et al., 2017) and approximates achievable in vivo tissue levels of NPY<sub>1-36</sub>, PYY<sub>1-36</sub> and SDF-1α (Schmidt et al., 2005; Kuncova et al., 2011; Roux et al., 2012). The fact that we were able to detect significant effects at these low concentrations speaks to the potency and likely in vivo importance of these peptides in stimulating cellular activity, particularly when combined with additional treatment conditions.

A major finding of the current study is that in all 3 cell types there were accumulative effects of treatments such that the combinations of treatments increased cellular activity more than individual treatments. In general, in all 3 cell types, cellular activity was increased in a step-wise fashion by hypertensive genotype, the addition of NPY<sub>1-36</sub> or PYY<sub>1-36</sub> to the hypertensive genotype, the further addition of SDF-1α to the hypertensive genotype treated with NPY<sub>1-36</sub> or PYY<sub>1-36</sub> and finally by the addition of sitagliptin to the hypertensive genotype treated with NPY<sub>1-36</sub> or PYY<sub>1-36</sub> in the presence of SDF-1α.
In general, the most efficacious stimulus of proliferation and collagen production (assessed by $[^3]$H-proline incorporation) was the combination of a hypertensive genotype co-treated with sitagliptin+NPY$_{1-36}$+SDF-1α. As noted, our method of $[^3]$H-proline incorporation does not allow for an accurate assessment of secreted collagens. Importantly, however, we observed a statistically significant sitagliptin-induced increase in extracellular collagen I levels (measured by a sandwich ELISA) in SHR CFs conditioned with the DPP4 substrates NPY$_{1-36}$ and SDF-1α. In these experiments sitagliptin also markedly increased the ratio of extracellular to intracellular (cytosolic) collagen I. This suggests that activation of collagen I synthesis by DPP4Is plus DPP4 substrates improves the efficiency of collagen I packaging by the ER/Golgi system and secretion into the extracellular compartment, with reduced “spillage” of collagen I into the cytosol.

The relevance of our finding is highlighted by the facts that in heart patients SDF-1α levels are increased and are associated with heart failure, cardiac fibrosis and all-cause mortality (Chu et al., 2010; Subramanian et al., 2014; Zuern et al., 2015). Studies in mice reveal that antagonism of the CXCR4 receptor (receptor for SDF-1α) promotes myocardial tissue repair and reduces myocardial scarring following myocardial infarction (Wang et al., 2019). The significance of our findings is also supported by the fact that the release of NPY$_{1-36}$ from sympathetic nerves is augmented in heart failure (Hulting et al., 1990; Kaye et al., 1994) and in patients with chronic kidney disease, plasma NPY is an strong predictor of cardiovascular events (Zoccali et al., 2019). Moreover, often patients with heart disease have the co-morbidity of hypertension. Consequently, the setting of a hypertensive genotype combined with elevated levels of NPY$_{1-36}$ and SDF-1α is a realistic, and likely, scenario.

In addition to hypertension with elevated levels of NPY$_{1-36}$ and SDF-1α, heart patients often have type 2 diabetes as an additional co-morbidity. Thus, such patients would be candidates for treatment with DPP4Is. The current study suggests that it is patients with this combination of conditions (hypertension with elevated levels of NPY$_{1-36}$ and SDF-1α) that may
be at highest risk of adverse effects due to chronic administration of DPP4Is. With regard to the heart, the present data suggest that DPP4Is may have direct adverse effects on the myocardium by promoting proliferation of, and collagen production by, CFs. As reviewed by Packer (Packer, 2018), the deleterious cardiac effects of DPP4Is may also be indirect. In this regard, DPP4Is augment the actions of SDF-1α, NPY1-36, and substance P in the central nervous system to increase sympathetic nerve traffic. This may, via β-adrenoceptor activation, elicit cardiomyocyte injury. Because sympathetic activation would also release NPY1-36 into the myocardium, this would reinforce the direct adverse actions of DPP4Is as described herein. Thus, these indirect (via the CNS) and direct (via stimulation of CFs) mechanisms may interact to increase the risk of DPP4I-induced adverse cardiac effects.

Sex is another important biological variable that may influence proliferation of, and collagen production by, cardiac and renal cells. Thus, it is conceivable that the effects of DPP4Is in females with genetic hypertension and elevated levels of NPY1-36 and SDF-1α may be different than the effects in males. To test of this, we compared the effects of NPY1-36 versus SDF-1α versus NPY1-36+SDF-1α in female and male SHR CFs treated or not with sitagliptin. These experiments revealed that female CFs are responsive to these pro-growth stimuli.

Although our in vitro findings indicate that sex chromosomes per se do not influence the responsiveness of CFs to DPP4Is, NPY1-36, SDF-1α or their combination, these experiments were performed in cell culture medium devoid of sex hormones. This leaves open the question as to whether in vivo sex hormones protect premenopausal females from the growth promoting effects of DPP4Is, NPY1-36, SDF-1α or their combination. Our previous studies show that 17β-estradiol, the major ovarian estrogen, is a potent inhibitor of CF, GMC and vascular smooth muscle cell proliferation induced by serum. Moreover, these effects of 17β-estradiol are mediated by the conversion of 17β-estradiol to 2ME (Dubey et al., 1998; Dubey et al., 2000; Dubey et al., 2001; Xiao et al., 2001; Zacharia et al., 2001; Barchiesi et al., 2002; Zacharia et al., 2002; Dubey et al., 2003a; Dubey et al., 2003b; Zacharia et al., 2003; Dubey et al., 2004;
Barchiesi et al., 2006; Dubey et al., 2007; Dubey and Jackson, 2009; Barchiesi et al., 2010; Rigassi et al., 2015), a major non-estrogenic metabolite of 17β-estradiol. Therefore, it is conceivable that because of endogenous 2ME, premenopausal women are resistant to the growth-promoting effects of DPP4 inhibition, NPY\textsubscript{1-36}, SDF-1α or their combination. Consistent with the notion that 2ME protects against the pro-growth effects of DPP4 inhibition, NPY\textsubscript{1-36}, SDF-1α or their combination, we observed that a very low concentration (1 nmol/L) of 2ME completely blocked the pro-growth effects of the most efficacious growth-promoting combination (i.e, genetic hypertension+DPP4 inhibition+NPY\textsubscript{1-36}+SDF-1α).

Previous studies by us and others show that 2ME and its metabolic precursor 2-hydroxyestradiol (2HE) are antidiabetic and exhibit anti-fibrotic and antihypertensive effects in various models of hypertension and related cardiovascular and renal injury and fibrosis. In this regard, 2HE reverses the metabolic syndrome (Tofovic et al., 2001); in mice on high fat diet, genetic deficiency or inhibition of COMT (key enzyme for 2HE to 2ME conversion) leads to insulin resistance and 2ME treatment improves metabolic derangements (Kanasaki et al., 2017); and 2ME improves glucose tolerance in db/db mice (Yorifuji et al., 2011). Furthermore, in vivo, 2ME and/or 2HE attenuate cardiac, renal, lung and systemic fibrosis induced by pro-fibrotic toxins (puromycin, bleomycin), NO deficiency or by angiotensin II (Tofovic et al., 2009; Zhu et al., 2015a; Maayah et al., 2018; Salah et al., 2019). Finally, 2ME reduces blood pressure in rats with genetically-, metabolic syndrome-, NO deficiency-, DOCA- or Ang II-induced hypertension (Bonacasa et al., 2008; Yuan et al., 2013; Maayah et al., 2018; Salah et al., 2019). Therefore, the combination of 2ME and DPP4Is may be a highly effective strategy to manage type 2 diabetes and prevent its sequelae.

Although the present study explores conditions and aspects of DPP4 inhibition that may contribute to unwanted effects of this class of drugs, there is strong evidence that DPP4Is also promote beneficial effects, likely by augmenting cardioprotective hormones such as glucagon-like peptide-1 (GLP-1) (Esposito et al., 2017). As recently reviewed by Nistala and Savin...
(Nistala and Savin, 2017), there is abundant preclinical evidence indicating that DPP4Is protect the heart, vasculature and kidneys, at least in rodent models of obesity, diabetes and hypertension. For example, DPP inhibition protects against renal injury (including fibrosis) in diabetic, ENOS knockout mice (Gangadharan Komala et al., 2016), mice with ureteral obstruction (Min et al., 2014) and streptozotocin-induced diabetes CD-1 mice (Shi et al., 2015); DPP inhibition also prevents cardiac fibrosis in Dahl salt sensitive rats (Esposito et al., 2017). Nonetheless, two recent, large, randomized, placebo-controlled multicenter studies with linagliptin show that in patients with type 2 diabetes, DPP4 inhibition does not provide cardiovascular or renal benefits (Rosenstock et al., 2019a; Rosenstock et al., 2019b). Avogaro and Fadini (Avogaro and Fadini, 2018) conclude that DPP4Is have pleiotropic effects mediated by diverse DPP4 substrates that are offsetting, thus accounting for the discrepancies between animal and human (involving >40,000 type 2 diabetic patients) studies. This situation is described by Jackson as “context-dependent” effects of DPP4Is (Jackson, 2017). Indeed, DPP4Is may even exert anti-fibrotic indirect and direct effects that promote wound healing (Marfella et al., 2012; Long et al., 2018) and reduce fibrosis in systemic sclerosis (Soare et al., 2019).

There are several limitations of the present study. First, the experiments were carried out in vitro. Given the large number of groups under study and the variability associated with in vivo experiments, the questions addressed in the present study could not be practically approached with in vivo experiments. Nonetheless, extrapolation to patients must be taken with circumspection and more focused in vivo experiments, guided by the present findings, are required. Second, here we concentrated on what we judged as three of the most important “off-target” DPP4 substrates, namely NPY<sub>1-36</sub>, PYY<sub>1-36</sub> and SDF-1α, that could be potential druggable targets for improving DPP4I pharmacotherapy. However, there are at least 50 DPP4 substrates, some of which are considered physiological (e.g., substance P), others pharmacological (Mulvihill and Drucker, 2014). In addition, DPP4 physically interacts with a
number binding partners (e.g., adenosine deaminase, CXCR4, integrin β1, sodium-hydrogen exchanger-3, CD45, fibronectin, collagen, caveolin-1, mannose-6-phosphate/insulin-like growth factor II receptor) (Kanasaki, 2018). Thus, the number of possible permutations involving DPP4 substrates and binding partners is extremely large. Again, the goal of the present study was limited to permutations involving hypertension, NPY$_{1-36}$, PYY$_{1-36}$, SDF-1α and DPP4. We acknowledge that many other permutations of DPP substrates (particularly substance P) and binding partners may influence the net effect of DPP4Is (and hence contribute to “context dependence”). Finally, although the SHR has been used in >17,000 published studies, the appropriate genetic control for this strain remains controversial, although most investigators use the corresponding WKY strain.

In summary, our study demonstrates that CFs, PGVSMCs and GMCs are activated by combinations of conditions, the most powerful of which is the co-existence of NPY$_{1-36}$, SDF-1α, DPP4 inhibition and a hypertensive genotype. We hypothesize that as these pro-growth conditions accumulate, a tipping point may be reached that manifests in the worst case as cardiac or renal dysfunction and in the best case as offsetting the beneficial effects of DPPIs. This could explain why some clinical studies confirm an increased risk of adverse cardiac effects of DPP4Is (Scirica et al., 2014; Zannad et al., 2015; McMurray et al., 2018), whereas others do not (Green et al., 2015; Gantz et al., 2017). Our experiments suggest that the full beneficial effects of DPP4Is could be maximized by combining DPP4Is with 2ME.
AUTHORSHIP CONTRIBUTIONS

Participated in research design: EKJ, DGG, SPT

Conducted Experiments: DGG

Performed data analysis: EKJ

Wrote or contributed to the writing of the manuscript: EKJ, SPT
REFERENCES

Avogaro A and Fadini GP (2018) The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. *Br J Clin Pharmacol* **84**:1686-1695.

Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B and Dubey RK (2006) 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. *Circ Res* **99**:266-274.

Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J and Dubey RK (2002) Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. *Hypertension* **39**:874-879.

Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Schaufelberger S, Gillespie DG, Jackson EK and Dubey RK (2010) Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. *Hypertension* **56**:964-972.

Berglund MM, Hipskind PA and Gehlert DR (2003) Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. *Exp Biol Med* **228**:217-244.

Bonacasa B, Sanchez ML, Rodriguez F, Lopez B, Quesada T, Fenoy FJ and Hernandez I (2008) 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. *Maturitas* **61**:310-316.
Brown RD, Ambler SK, Mitchell MD and Long CS (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. *Annu Rev Pharmacol Toxicol* **45**:657-687.

Busillo JM and Benovic JL (2007) Regulation of CXCR4 signaling. *Biochim Biophys Acta* **1768**:952-963.

Chen D, Zang YH, Qiu Y, Zhang F, Chen AD, Wang JJ, Chen Q, Li YH, Kang YM and Zhu GQ (2019) BCL6 Attenuates Proliferation and Oxidative Stress of Vascular Smooth Muscle Cells in Hypertension. *Oxid Med Cell Longev* **2019**:5018410.

Cheng D, Zhu X, Gillespie DG and Jackson EK (2013) Role of RACK1 in the differential proliferative effects of neuropeptide Y\textsubscript{1-36} and peptide YY\textsubscript{1-36} in SHR vs. WKY preglomerular vascular smooth muscle cells. *Am J Physiol Renal Physiol* **304**:F770-780.

Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T and Kaye DM (2010) Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. *Am J Pathol* **176**:1735-1742.

Devin JK, Pretorius M, Nian H, Yu C, Billings FTt and Brown NJ (2014) Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. *Hypertension* **63**:951-957.
Dubey RK, Gillespie DG, Jackson EK and Keller PJ (1998) 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. *Hypertension* **31**:522-528.

Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B and Jackson EK (2003a) CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. *Hypertension* **41**:807-813.

Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J and Jackson EK (2000) Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. *Biochem Biophys Res Commun* **278**:27-33.

Dubey RK, Imthurn B and Jackson EK (2007) 2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. *Endocrinology* **148**:4125-4127.

Dubey RK and Jackson EK (2009) Potential vascular actions of 2-methoxyestradiol. *Trends in Endocrinology & Metabolism* **20**:374-379.

Dubey RK, Jackson EK, Gillespie DG, Zacharia LC and Imthurn B (2004) Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells. *J Clin Endocrinol Metab* **89**:3922-3931.
Dubey RK, Jackson EK, Keller PJ, Imthurn B and Rosselli M (2001) Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. *Hypertension* **37**:640-644.

Dubey RK, Jackson EK, Rupprecht HD and Sterzel RB (1997) Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. *Curr Opin Nephrol Hypertens* **6**:88-105.

Dubey RK, Rosselli M, Gillespie DG, Mi Z and Jackson EK (2010) Extracellular 3′,5′-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. *J Pharmacol Exp Ther* **333**:808-815.

Dubey RK, Zacharia LC, Gillespie DG, Imthurn B and Jackson EK (2003b) Catecholamines block the antimitogenic effect of estradiol on human glomerular mesangial cells. *Hypertension* **42**:349-355.

Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda LP, Roviezzo F, Piegari E, Berrino L, Rossi F, De Angelis A and Urbanek K (2017) Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. *Br J Pharmacol* **174**:4070-4086.

Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A and Avogaro A (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin
increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. *Diabetes Care* **33**:1607-1609.

Gangadharan Komala M, Gross S, Zaky A, Pollock C and Panchapakesan U (2016) Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. *Nephrology (Carlton, Vic)* **21**:423-431.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD and Lai E (2017) A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol* **16**:112.

Gorrell MD (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. *Clin Sci* **108**:277-292.

Gouya G, Voithofer P, Neuhold S, Storka A, Vila G, Pacher R, Wolzt M and Hülsmann M (2014) Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure. *Int J Clin Pract* **68**:1293-1300.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR and Group TS (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* **373**:232-242.
Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FTt, Jafarian Kerman S and Brown NJ (2018) DPP (dipeptidyl peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition. *Hypertension* **72**:712-719.

Hulting J, Sollevi A, Ullman B, Franco-Cereceda A and Lundberg JM (1990) Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. *Cardiovasc Res* **24**:102-108.

Inoue T, Mi Z, Gillespie DG and Jackson EK (1998) Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. *Eur J Pharmacol* **361**:285-291.

Jackson EK (2017) Context-dependent effects of dipeptidyl peptidase 4 inhibitors. *Curr Opin Nephrol Hypertens* **26**:83-90.

Jackson EK, Kochanek SJ and Gillespie DG (2012) Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. *Hypertension* **60**:757-764.

Jackson EK, Mi Z, Tofovic SP and Gillespie DG (2015) Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. *Hypertension* **65**:238-249.
Jackson EK, Zhang Y, Gillespie DD, Zhu X, Cheng D and Jackson TC (2017) SDF-1α (stromal cell-derived factor 1α) induces cardiac fibroblasts, renal microvascular smooth muscle cells, and glomerular mesangial cells to proliferate, cause hypertrophy, and produce collagen. *Journal of the American Heart Association* 6:e007253.

Kanasaki K (2018) The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. *Clin Sci* 132:489-507.

Kanasaki M, Srivastava SP, Yang F, Xu L, Kudoh S, Kitada M, Ueki N, Kim H, Li J, Takeda S, Kanasaki K and Koya D (2017) Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice. *Scientific reports* 7:7927.

Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G and Esler MD (1994) Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. *J Am Coll Cardiol* 23:570-578.

Klemann C, Wagner L, Stephan M and von Horsten S (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. *Clin Exp Immunol* 185:1-21.

Kost CK, Jr., Li P and Jackson EK (1995) Blood pressure after captopril withdrawal from spontaneously hypertensive rats. *Hypertension* 25:82-87.
Kuncova J, Sykora R, Chvojka J, Sviglerova J, Stengl M, Krouzecky A, Nalos L and Matejovic M (2011) Plasma and tissue levels of neuropeptide Y in experimental septic shock: relation to hemodynamics, inflammation, oxidative stress, and hemofiltration. *Artif Organs* **35**:625-633.

Long M, Cai L, Li W, Zhang L, Guo S, Zhang R, Zheng Y, Liu X, Wang M, Zhou X, Wang H, Li X, Li L, Zhu Z, Yang G and Zheng H (2018) DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring. *Diabetes* **67**:518-531.

Maayah ZH, Levasseur J, Siva Piragasam R, Abdelhamid G, Dyck JRB, Fahlman RP, Siraki AG and El-Kadi AOS (2018) 2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy. *Scientific reports* **8**:2780.

Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, Carbonara O, Gualdiero P, Petronella P, Ferraraccio F, Petrella A, Canonico R, Campitiello F, Della Corte A, Paolisso G and Canonico S (2012) Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. *Experimental diabetes research* **2012**:892706.

Marney A, Kunchakarra S, Byrne L and Brown NJ (2010) Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. *Hypertension* **56**:728-733.
McIntosh CH, Demuth HU, Pospisilik JA and Pederson R (2005) Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128:159-165.

McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD and Krum H (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart failure 6:8-17.

Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 85:9-24.

Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T and Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150.

Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, Lee JE, Kim HW, Cha JJ, Chung YY, Hyun YY, Han JY and Cha DR (2014) Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest 94:598-607.

Mulvihill EE and Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992-1019.
Namba T, Tsutsui H, Tagawa H, Takahashi M, Saito K, Kozai T, Usui M, Imanaka-Yoshida K, Imaizumi T and Takeshita A (1997) Regulation of fibrillar collagen gene expression and protein accumulation in volume-overloaded cardiac hypertrophy. *Circulation* **95**:2448-2454.

Nistala R and Savin V (2017) Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. *Am J Physiol Renal Physiol* **312**:F661-F670.

Packer M (2018) Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. *Circ Res* **122**:928-932.

Peterkofsky B (1972) The effect of ascorbic acid on collagen polypeptide synthesis and proline hydroxylation during the growth of cultured fibroblasts. *Arch Biochem Biophys* **152**:318-328.

Peterkofsky B and Diegelmann R (1971) Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. *Biochemistry (Mosc)* **10**:988-994.

Rigassi L, Barchiesi Bozzolo F, Lucchinetti E, Zaugg M, Fingerle J, Rosselli M, Imthurn B, Jackson EK and Dubey RK (2015) 2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cells. *Am J Physiol Endocrinol Metab* **309**:E995-1007.
Rodriguez-Feo JA, Sluijter JP, de Kleijn DP and Pasterkamp G (2005) Modulation of collagen turnover in cardiovascular disease. *Curr Pharm Des* **11**:2501-2514.

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK and Marx N (2019a) Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *JAMA*.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaitd S, Meinecke T, George JT, von Eynatten M and McGuire DK (2019b) Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA* **321**:69-79.

Roux N, Leveque S, Freguin-Bouilland C, Dautreaux B, Proust F, Thuillez C and Plissonnier D (2012) A kinetic study of SDF-1, VEGF and MCP-1 blood and tissue levels after aortic transplantation in mice. *Acta Histochem* **114**:636-638.

Salah E, Bastacky SI, Jackson EK and Tofovic SP (2019) 2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury. *J Cardiovasc Pharmacol* **73**:165-177.
Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ and Hellstrom PM (2005) Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. *Eur J Gastroenterol Hepatol* **17**:207-212.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG and Bhatt DL (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation* **130**:1579-1588.

Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K and Koya D (2015) Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. *Kidney Int* **88**:479-489.

Soare A, Gyorfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, Ludolph I, Horch RE, Bauerle T, von Horsten S, Mihai C, Distler O, Ramming A, Schett G and Distler JHW (2019) Dipeptidyl-peptidase-4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in Systemic Sclerosis. *Arthritis & Rheumatology (Hoboken, NJ).*

Subbarayan S and Kipnes M (2011) Sitagliptin: a review. *Expert Opin Pharmacother* **12**:1613-1622.
Subramanian S, Liu C, Aviv A, Ho JE, Courchesne P, Muntendam P, Larson MG, Cheng S, Wang TJ, Mehta NN and Levy D (2014) Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. *Arterioscler Thromb Vasc Biol* 34:2100-2105.

Tofovic SP, Dubey RK and Jackson EK (2001) 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. *J Pharmacol Exp Ther* 299:973-977.

Tofovic SP, Zhang X, Jackson EK, Zhu H and Petrusevska G (2009) 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. *Vascul Pharmacol* 51:190-197.

Umeda M, Kanda T and Murakami M (2003) Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. *Hypertension Research - Clinical & Experimental* 26:485-492.

Wang W, Choi BK, Li W, Lao Z, Lee AY, Souza SC, Yates NA, Kowalski T, Pocai A and Cohen LH (2014) Quantification of intact and truncated stromal cell-derived factor-1α in circulation by immunoaffinity enrichment and tandem mass spectrometry. *J Am Soc Mass Spectrom* 25:614-625.

Wang Y, Dembowsky K, Chevalier E, Stuve P, Korf-Klingebiel M, Lochner M, Napp LC, Frank H, Brinkmann E, Kanwischer A, Bauersachs J, Gyongyosi M, Sparwasser T and
Wollert KC (2019) C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. *Circulation* **139**:1798-1812.

Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M and Devin JK (2018) Dipeptidyl peptidase-4 inhibition potentiates stimulated growth hormone secretion and vasodilation in women. *Journal of the American Heart Association* **7**:25.

Wilson JR, Kerman SJ, Hubers SA, Yu C, Nian H, Grouzmann E, Eugster PJ, Mayfield DS and Brown NJ (2019) Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. *Journal of the Endocrine Society* **3**:1784-1798.

Xiao S, Gillespie DG, Baylis C, Jackson EK and Dubey RK (2001) Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. *Hypertension* **37**:645-650.

Yorifuji T, Uchida T, Abe H, Toyofuku Y, Tamaki M, Fujitani Y, Hirose T, Kawamori R, Takeda S and Watada H (2011) 2-Methoxyestradiol ameliorates glucose tolerance with the increase in beta-cell mass in db/db mice. *Journal of diabetes investigation* **2**:180-185.
Yuan W, Yu Y, Li J, Singh P, Li D, Gui Y and Zheng XL (2013) Estrogen metabolite 2-methoxyestradiol prevents hypertension in deoxycorticosterone acetate-salt rats. *Cardiovasc Drugs Ther* 27:17-22.

Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F and Dubey RK (2003) Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. *Circulation* 108:2974-2978.

Zacharia LC, Jackson EK, Gillespie DG and Dubey RK (2001) Catecholamines abrogate antimitogenic effects of 2-hydroxyestradiol on human aortic vascular smooth muscle cells. *Arteriosclerosis, Thrombosis & Vascular Biology* 21:1745-1750.

Zacharia LC, Jackson EK, Gillespie DG and Dubey RK (2002) Catecholamines block 2-hydroxyestradiol-induced antimitogenesis in mesangial cells. *Hypertension* 39:854-859.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB and Investigators E (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet* 385:2067-2076.

Zhu L, Song Y and Li M (2015a) 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation. *J Dermatol Sci* 77:63-70.
Zhu X, Gillespie DG and Jackson EK (2015b) NPY₁-36 and PYY₁-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. *Am J Physiol Heart Circ Physiol* **309**:H1528-1542.

Zhu X and Jackson EK (2017) RACK1 regulates angiotensin II-induced contractions of SHR preglomerular vascular smooth muscle cells. *Am J Physiol Renal Physiol* **312**:F565-f576.

Zoccali C, D'Arrigo G, Leonardis D, Pizzini P, Postorino M, Tripepi G and Mallamaci F (2019) Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. *J Hypertens* **37**:1359-1365.

Zuern CS, Walker B, Sauter M, Schaub M, Chatterjee M, Mueller K, Rath D, Vogel S, Tegtmeyer R, Seizer P, Geisler T, Kandolf R, Lang F, Klingel K, Gawaz M and Borst O (2015) Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. *Clin Res Cardiol* **104**:1033-1043.

The work was supported by the National Institutes of Health [DK091190, HL069846, DK068575, HL109002 and DK079307].
LEGENDS for FIGURES

Figure 1. This figure illustrates the experimental design for Protocol 1. The protocol entailed 12 batches of CFs, with each batch derived from a separate male rat (i.e., a total of 12 rats; 6 WKY and 6 SHR). In the case of GMCs or PGVSMCs, the protocol again entailed 12 distinct batches of cells; however, because sufficient numbers of GMCs and PGVSMCs cannot be obtained from 1 rat, each batch of cells was derived from a separate set of 3 male rats [i.e., a total of 12 sets of 3 rats; 6 sets of 3 WKY and 6 sets of 3 SHR]. Thus a single biological replicate is a unique rat or a unique set of 3 rats. Cells from each WKY biological replicate were seeded on a 12-well plate, and cells from each SHR biological replicate were seeded on another identical 12-well plate. There were 12 treatment groups for each plate (i.e., for each plate, each well of cells received 1 of 12 treatments). All plates received the same 12 treatments. Next, the plate of WKY cells and a plate of SHR cells were placed side-by-side in a cell incubator. After the indicated incubation time, either cell proliferation or collagen synthesis was measured. We considered this one experiment. Next, the entire procedure was repeated 5 times on different occasions (i.e., sample size was n=6 for WKY cells and n=6 for SHR cells). Pairs of plates performed at the same time are noted by vertical lines.

Figure 2. This figure illustrates the design of Protocol 2. CFs from a specific male or female SHR were seeded on separate 12-well plates, and 9 wells of each plate received 1 of 9 treatments; and the 2 plates were placed together in a cell incubator. All plates received the same 9 treatments. After the indicated incubation time, cell proliferation was measured. We considered this one experiment. Next, the entire procedure was repeated 4 times on different occasions (i.e., sample size was n=5 for male CFs and n=5 for female CFs). Pairs of plates performed at the same time are noted by vertical lines.
Figure 3. Bar graph compares effects of 24 combinatorial treatments/conditions on the proliferation of cardiac fibroblasts. WKY, cells from male normotensive Wistar-Kyoto rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

Figure 4. Bar graph compares effects of 24 combinatorial treatments/conditions on proline incorporation, an index of collagen production, by cardiac fibroblasts. WKY, cells from male normotensive Wistar-Kyoto rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

Figure 5. Bar graph compares effects of 24 combinatorial treatments/conditions on the proliferation of preglomerular vascular smooth muscle cells. WKY, cells from male normotensive Wistar-Kyoto rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

Figure 6. Bar graph compares effects of 24 combinatorial treatments/conditions on proline incorporation, an index of collagen production, by preglomerular vascular smooth muscle cells. WKY, cells from male normotensive Wistar-Kyoto rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

Figure 7. Bar graph compares effects of 24 combinatorial treatments/conditions on the proliferation of glomerular mesangial cells. WKY, cells from male normotensive Wistar-Kyoto
rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

**Figure 8.** Bar graph compares effects of 24 combinatorial treatments/conditions on proline incorporation, an index of collagen production, by glomerular mesangial cells. WKY, cells from male normotensive Wistar-Kyoto rats; SHR, cells from male spontaneously hypertensive rats (rats with genetic hypertension); PYY, peptide YY$_{1-36}$; NPY, neuropeptide Y$_{1-36}$; SDF-1α, stromal cell-derived factor-1α. Values are means and SEMs.

**Figure 9.** Bar graph compares the pro-proliferative effects of neuropeptide Y$_{1-36}$ (NPY) alone, stromal cell-derived factor-1α (SDF-1α) alone and NPY+SDF-1α in female cardiac fibroblasts from spontaneously hypertensive rats (SHR) without (panel A) and with (panel B) sitagliptin. Panels C and D show comparable data for male SHR CFs. Values are means and SEMs. The letters a, b, c and d indicate significantly different from Control, NPY-treated, SDF-1α-treated and NPY+SDF-1α cells, respectively.

**Figure 10.** Bar graph compares the pro-proliferative effects of neuropeptide Y$_{1-36}$ (NPY) plus stromal cell-derived factor-1α (SDF-1α) plus sitagliptin in male (panel A) and female (panel B) cardiac fibroblasts from spontaneously hypertensive rats (SHR) in the absence and presence of 1 nmol/L of 2-methoxyestradiol (2ME). Values are means and SEMs. The letters a and b indicate significant difference from Control and 2ME-treated cells, respectively.

**Figure 11.** Bar graphs show the effects of sitagliptin on collagen I secretion by cardiac fibroblasts from spontaneously hypertensive rats that were co-treated with DPP4 substrates (neuropeptide Y$_{1-36}$ and stromal cell-derived factor-1α). Sitagliptin decreased intracellular (likely
cytosolic) collagen I (panel A) while simultaneously increasing extracellular levels of collagen I (panel B). Thus, the ratio of extracellular to intracellular (cytosolic) collagen I was markedly increased (panel C), suggesting increased efficiency of collagen I packaging and secretion via exocytosis. Values are means and SEMs.
Figure 1

Rat(s) 1: WKY

12 Treatments Per Plate

Rat(s) 3: WKY

12 Treatments Per Plate

Rat(s) 5: WKY

12 Treatments Per Plate

Rat(s) 7: WKY

12 Treatments Per Plate

Rat(s) 9: WKY

12 Treatments Per Plate

Rat(s) 11: WKY

12 Treatments Per Plate

Rat(s) 2: SHR

12 Treatments Per Plate

Rat(s) 4: SHR

12 Treatments Per Plate

Rat(s) 6: WKY

12 Treatments Per Plate

Rat(s) 8: SHR

12 Treatments Per Plate

Rat(s) 10: WKY

12 Treatments Per Plate

Rat(s) 12: SHR

12 Treatments Per Plate
Figure 2
Cardiac Fibroblasts - Cell Number

ANOVA
Genotype: $P<0.0001$
Treatments: $P<0.0001$
Genotype x Treatment: $P<0.0001$

Figure 3

$P<0.05$ vs All Groups

$P<0.05$ vs All WKY Groups
Cardiac Fibroblasts - Proline Incorporation

ANOVA
Genotype: $P<0.0001$
Treatments: $P<0.0001$
Genotype x Treatment: $P=0.0010$

Figure 4

Proline Incorporation (dpm)

P<0.05 vs All Groups
P<0.05 vs All WKY Groups
Preglomerular Vascular Smooth Muscle Cells - Cell Number

ANOVA
- Genotype: P=0.0001
- Treatments: P<0.0001
- Genotype x Treatment: P<0.0001

Figure 5

P<0.05 vs All Groups

P<0.05 vs All WKY Groups
Preglomerular Vascular Smooth Muscle Cells - Proline Incorporation

ANOVA
Genotype: $P<0.0001$
Treatments: $P<0.0001$
Genotype x Treatment: $P=0.0011$

Figure 6

P<0.05 vs All Groups
P<0.05 vs All WKY Groups

This article has not been copyedited and formatted. The final version may differ from this version.
Glomerular Mesangial Cells - Cell Number

ANOVA
Genotype: $P<0.0001$
Treatments: $P<0.0001$
Genotype x Treatment: $P<0.0001$

Cell Number

$P<0.05$ vs All Groups

$P<0.05$ vs All WKY Groups

Figure 7
Glomerular Mesangial Cells - Proline Incorporation

ANOVA
Genotype: $P=0.6557$
Treatments: $P<0.0001$
Genotype x Treatment: $P=0.0006$

Figure 8

Proline Incorporation (dpm)

Both $P<0.05$ vs All Groups
Except Each Other and #
ANOVA
Sitagliptin: $P<0.0001$
Treatments: $P<0.0001$
Sitagliptin x Treatments: $P=0.0026$

A

FEMALE SHR Cardiac Fibroblasts

| Treatment     | Cell Number |
|---------------|-------------|
| Control       | (n=5)       |
| NPY           | a,c,d       |
| SDF-1α        | a,b         |
| NPY+SDF-1α    | a,b         |

B

FEMALE SHR Cardiac Fibroblasts with Sitagliptin

| Treatment                  | Cell Number |
|----------------------------|-------------|
| Sitagliptin                | (n=5)       |
| Sitagliptin+NPY            | a,d         |
| Sitagliptin+SDF-1α         | a,d         |
| Sitagliptin+NPY+SDF-1α     | a,b,c       |

C

ANOVA
Sitagliptin: $P=0.0009$
Treatments: $P<0.0001$
Sitagliptin x Treatments: $P=0.0009$

MALE SHR Cardiac Fibroblasts

| Treatment     | Cell Number |
|---------------|-------------|
| Control       | (n=5)       |
| NPY           | a,d         |
| SDF-1α        | a,d         |
| NPY+SDF-1α    | a,b,c       |

D

MALE SHR Cardiac Fibroblasts with Sitagliptin

| Treatment                  | Cell Number |
|----------------------------|-------------|
| Sitagliptin                | (n=5)       |
| Sitagliptin+NPY            | a,c,d       |
| Sitagliptin+SDF-1α         | a,b,d       |
| Sitagliptin+NPY+SDF-1α     | a,b,c       |

Figure 9
**Figure 10**

**A**

**MALE SHR Cardiac Fibroblasts**

1-Factor ANOVA: $P<0.0001$

| Treatment               | Cell Number |
|-------------------------|-------------|
| Control                 | 120,000     |
| Sitagliptin+NPY+SDF-1α  | 200,000     |
| Sitagliptin+NPY+SDF-1α+2ME | 140,000   |

**B**

**FEMALE SHR Cardiac Fibroblasts**

1-Factor ANOVA: $P<0.0001$

| Treatment               | Cell Number |
|-------------------------|-------------|
| Control                 | 120,000     |
| Sitagliptin+NPY+SDF-1α  | 180,000     |
| Sitagliptin+NPY+SDF-1α+2ME | 140,000   |
**Figure 11**

| **A** | Intracellular Collagen I (ng/ml) |
|-------|---------------------------------|
|       | Control (n=5)                    |
|       | Sitagliptin (n=5)                |
|       | P=0.0034                         |

| **B** | Extracellular Collagen I (ng/ml) |
|-------|---------------------------------|
|       | Control (n=5)                    |
|       | Sitagliptin (n=5)                |
|       | P=0.0130                         |

| **C** | Extracellular to Intracellular Ratio of Collagen I |
|-------|---------------------------------------------------|
|       | Control (n=5)                                    |
|       | Sitagliptin (n=5)                                 |
|       | P=0.0058                                          |